About: Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients
Creator	Arnold, Ahran Arnold, Jayantha Hendry, Bruce Manglam, Vijay Sangwaiya, Arvind Stafford, Nina Stuart, \| Rosen, D
source	Medline; PMC
abstract	We propose a new hypothesis that the established drug pentoxifylline deserves attention as a potential repurposed therapeutic for COVID‐19. Pentoxifylline is an immunomodulator with anti‐inflammatory properties. It is a nonselective phosphodiesterase inhibitor and through Adenosine A2A Receptor‐mediated pathways reduces tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferon gamma and may act to reduce tissue damage during the cytokine storm host response to SARS‐CoV‐2 infection. This agent has been used clinically for many years and has a favorable profile of safety and tolerability. Pre‐clinical data support pentoxifylline as effective in cytokine‐driven lung damage. Clinical studies of pentoxifylline in radiation and cytokine‐induced lung damage in humans are positive and consistent with anti‐inflammatory efficacy. Pentoxifylline is a readily available, off‐patent and inexpensive drug, suitable for large‐scale use including in resource‐limited countries. Current trials of therapeutics are largely focused on the inhibition of viral processes. We advocate urgent randomized trials of pentoxifylline for COVID‐19 as a complementary approach to target the host responses.
has issue date	2020-07-26(xsd:dateTime)
bibo:doi	10.1002/prp2.631
bibo:pmid	32715661
has license	cc-by
sha1sum (hex)	81e1d9095bde796ef65c1e9c56e3cb794e5cc839
schema:url	https://doi.org/10.1002/prp2.631
resource representing a document's title	Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients
has PubMed Central identifier	PMC7383088
has PubMed identifier	32715661
schema:publication	Pharmacol Res Perspect
resource representing a document's body	covid:81e1d9095bde796ef65c1e9c56e3cb794e5cc839#body_text
is schema:about of	named entity 'pentoxifylline' named entity 'damage' named entity 'drug' named entity 'effective' named entity 'interleukin' named entity 'ANTI-INFLAMMATORY' named entity 'POTENTIAL' named entity 'FAVORABLE' named entity 'SUPPORT' named entity 'RESOURCE-LIMITED COUNTRIES' named entity 'HYPOTHESIS' named entity 'consistent' named entity 'reduce' named entity 'interleukin' named entity 'Adenosine' named entity 'attention' named entity 'lung' named entity 'phosphodiesterase inhibitor' named entity 'Adenosine' named entity 'cytokine storm' named entity 'interleukin 6' named entity 'Pre-clinical' named entity 'pentoxifylline' named entity 'COVID-19' named entity 'Pentoxifylline' named entity 'cytokine' named entity 'potential' named entity 'SARS-CoV-2' named entity 'sepsis' named entity 'pentoxifylline' named entity 'receptor' named entity 'adenosine receptor' named entity 'macrophages' named entity 'SARS CoV' named entity 'TNF alpha' named entity 'Pentoxifylline' named entity 'adenosine receptor' named entity 'erythropoietin' named entity 'oxygen exchange' named entity 'animal studies' named entity 'pentoxifylline' named entity 'gene transcription' named entity 'pentoxifylline' named entity 'pharmacology' named entity 'cytokine storm' named entity 'lung' named entity 'Interleukin-8' named entity 'pentoxifylline' named entity 'pentoxifylline' named entity 'A2AR' named entity 'pentoxifylline' named entity 'COVID-19' named entity 'cAMP' named entity 'Pentoxifylline' named entity 'acute myocardial injury' named entity 'Inflammasome' named entity 'pentoxifylline' named entity 'coronary artery disease' named entity 'pentoxifylline' named entity 'IFN gamma' named entity 'Pentoxifylline' named entity 'peripheral vascular disease' named entity 'pulmonary complications' named entity 'pneumonitis' named entity 'pro-inflammatory' named entity 'Remdesivir' named entity 'ViiV Healthcare' named entity 'cytokine storm' named entity 'macrophages' named entity 'macrophages' named entity 'pentoxifylline' named entity 'Interleukin-6' named entity 'renal disease' named entity 'pentoxifylline'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software